A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Current Standard of Care in Subjects with Mild or Asymptomatic COVID-19

For UCSF Faculty and Staff: Please login via MyAccess to request access to update your Project.

Public Summary

This is a study to test whether favipiravir, an oral pill that has broad antiviral activity, may be effective at reducing the symptoms of COVID-19 if given early to patients (similar to how Tamiflu is given early for the flu to help shorten the duration of the illness). Participants will receive either treatment pill or placebo pill to be taken twice a day for 10 days and then followed closely for a month.